Impact of biological therapies on laboratory outcomes and FEV1 in patients with severe eosinophilic asthma with chronic rhinosinusitis: a real-life study from Saudi Arabia
Keywords:
Severe asthma, Saudi Arabia, FEV1, Laboratory, Outcomes, Chronic rhinosinusitis, biologicsAbstract
Background: Few studies have addressed the effects of biological therapies on laboratory outcomes and changes in FEV1 in patients with severe asthma (SA) and chronic rhinosinusitis (CRS). We aimed to study the effect of three biological therapies on laboratory outcomes and FEV1 in Saudi Arabian patients with SA and CRS.
Methods: From March to September 2022, a retrospective observational cohort study was undertaken at the severe asthma clinics of the Armed Forces Hospital—Southern Region (AFHSR) and King Khalid University Hospital, Abha, Saudi Arabia, to delineate the effects of 3 biological therapies (benralizumab, dupilumab, and omalizumab) in adults with SA and concomitant CRS in terms of FEV1 and laboratory parameters (serum IgE and eosinophilic counts).
Results: Eighty patients were enrolled, with a mean age of 46.68. There were 45 (56%) females and 35 (44%) males. There were significant improvements in FEV1 and laboratory parameters (serum IgE and eosinophilic counts) after 6 &12 months of biological therapies compared to pre-biological therapies (p<0.001, each). The response was different among different biological therapies. The improvements in FEV1, serum IgE, and eosinophilic counts were manifest with benralizumab and dupilumab but not with omalizumab.
Conclusions: Results from the first study from two large Saudi Arabian tertiary centers for patients with severe asthma and chronic rhinosinusitis agree with and support those of worldwide real-life ones. One-year follow-up of patients with SA and CRS showed the effectiveness of benralizumab and dupilumab, but not omalizumab, regarding FEV1, serum IgE, and eosinophilic counts. Further prospective multicenter studies are warranted.
References
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2023. https://ginasthma.org/2023-gina-main-report/.
Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol 2021; 11(3): 213-739. doi: 10.1002/alr.22741.
Bhattacharyya N, Gilani S. Prevalence of Potential Adult Chronic Rhinosinusitis Symptoms in the United States. Otolaryngol Head Neck Surg 2018; 159(3):522-525. doi: 10.1177/0194599818774006.
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020; 58(Suppl S29): 1-464. doi: 10.4193/Rhin20.600.
Shaw D.E., Sousa A.R., Fowler S.J., et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 2015; 46(5): 1308-21. Doi: 10.1183/13993003.00779-2015.
Bachert C., Han J.K., Desrosiers M., Hellings P.W., Amin N., Lee S.E., et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps: results from two multicentre, randomized, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; 394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1.
Eldaboussi S, Qabil A, Lotfi A, Awad A, Abdel Salam E, Alkhamis A, Abuelhassan UE. Saudi Arabian real-life experience with biologic therapy in severe asthma. Multidiscip Respir Med 2021; 16(1): 807. doi: 10.4081/mrm.2021.807.
Förster-Ruhrmann U, Stergioudi D, Szczepek AJ, Fluhr JW, Zuberbier T, Olze H, Bergmann KC. A real-life comparison of pulmonary and nasal outcomes in those patients with severe asthma and nasal polyposis treated with T2-biologics. World Allergy Organ J 2023; 16(2): 100746. doi: 10.1016/j.waojou.2023.100746.
Rogers L, Jesenak M, Bjermer L, Hanania NA, Seys SF, Diamant Z. Biologics in severe asthma: A pragmatic approach for choosing the proper treatment for the right patient. Respir Med 2023; 218: 107414. doi: 10.1016/j.rmed.2023.107414.
Khan AR, Waqar S, Rafiq Z, Bangash SA, Askar H, Khan MZ, Khan S. Retrospective Analysis of Biologic Agent Utilization in Severe Asthma: Impact on Exacerbation Rates, Forced Expiratory Volume in the First Second (FEV1), Eosinophils, and IgE Levels. Cureus. 2023 Aug 1;15(8):e42818. doi: 10.7759/cureus.42818.
Domínguez-Ortega J, Mullol J, Álvarez Gutiérrez FJ, Miguel-Blanco C, Castillo JA, Olaguibel JM, Blanco-Aparicio M. The effect of biologics in lung function and quality of life of patients with united airways disease: A systematic review. J Allergy Clin Immunol Glob. 2023 Sep 28;3(1):100174. doi: 10.1016/j.jacig.2023.100174.
Schatz M., Kosinski M., Yarlas A.S., Hanlon J., Watson ME, Jhingran P. The minimally significant difference of the Asthma Control Test. J Allergy Clin Immunol 2009; 124(4): 719-23.e1. doi: 10.1016/j.jaci.2009.06.053.
Culver BH, Graham BL, Coates AL, Wanger J, Berry CE, Clarke PK, Hallstrand TS, Hankinson JL, Kaminsky DA, MacIntyre NR, McCormack MC, Rosenfeld M, Stanojevic S, Weiner DJ; ATS Committee on Proficiency Standards for Pulmonary Function Laboratories. Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement. Am J Respir Crit Care Med. 2017 Dec 1;196(11):1463-1472. Doi: 10.1164/rccm.201710-1981ST.
Khurana S, Bush A, Holguin F. Management of severe asthma: summary of the European Respiratory Society/American Thoracic Society task force report. Breathe (Sheff). 2020 Jun;16(2):200058. doi: 10.1183/20734735.0058-2020.
Lötvall J., Akdis C.A., Bacharier L.B., et al. Asthma endotypes are a new approach to classifying disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127(2): 355-60. doi: 10.1016/j.jaci.2010.11.037.
Fahy JV. Type two inflammation in asthma is present in most cases and absent in many others. Nat Rev Immunol 2015; 15(1): 57-65. doi: 10.1038/nri3786.
Agachie I., Beltran J., Akadis C., Akdis M., Canonica G.W., et al. The Efficacy and safety of therapies with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab) for severe asthma. Systematic review for the EAACI Guidelines - recommendations on using biologicals in severe asthma. Allergy 2020; 75(5): 1023-1042. doi: 10.1111/all.14221.
Akenroye AT, Segal JB, Zhou G, Foer D, Li L, Alexander GC, Keet CA, Jackson JW. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. J Allergy Clin Immunol. 2023 May;151(5):1269-1276. doi: 10.1016/j.jaci.2023.01.020.
Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med. 2022 Jan 13;386(2):157-171. doi: 10.1056/NEJMra2032506.
Nolasco S, Crimi C, Pelaia C, Benfante A, Caiaffa MF, Calabrese C, et al. Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4371-4380.e4. doi: 10.1016/j.jaip.2021.08.004.
Heffler E, Saccheri F, Bartezaghi M, Canonica GW. Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis. Clin Transl Allergy. 2020 Jun 26;10:25. Doi: 10.1186/s13601-020-00330-1.
Tiotiu A, Oster JP, Roux PR, Nguyen Thi PL, Peiffer G, Bonniaud P, Dalphin JC, de Blay F. Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study. J Investig Allergol Clin Immunol. 2020;30(1):49-57. doi: 10.18176/jiaci.0391.
Published
Issue
Section
License
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
How to Cite
